Last reviewed · How we verify

NCT04187976

Eosinophils Endotypes in Chronic Airway Inflammatory Diseases

Completed
What this trial tests

trial in Eosinophilic Asthma in 70 participants. Completed in 30 October 2023.

Timeline
3 March 2020
30 October 2023

Quick facts

Lead sponsorUniversity Hospital, Lille
StatusCompleted
Enrollment70
Start date3 March 2020
Estimated completion30 October 2023

Conditions studied

Sponsor

University Hospital, Lille

Who can join

Eligibility, any sex, with Eosinophilic Asthma or Chronic Sinusitis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Oncostatin-M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma.
    Esnault S, Bernau K, Floerke HL, Dendooven A, et al · · 2025 · cited 2× · PMID 39707874 · DOI 10.1111/all.16453
  2. Associations Between Blood Eosinophil Surface Proteins and Clinical Traits in Severe Asthma and Chronic Rhinosinusitis With Nasal Polyposis.
    Delaunay E, Esnault S, Dendooven A, Stoup T, et al · · 2025 · cited 1× · PMID 40751399 · DOI 10.1111/all.70001
  3. Identification of the Cytokines, Growth Factors and Their Receptors Expressed by Human Blood Eosinophils: A Transcriptomics Approach.
    Esnault S, Delaunay E, Dendooven A, Johansson MW, et al · · 2025 · PMID 41448238 · DOI 10.1111/cea.70115

Verify or expand the search:

Other recruiting trials for Eosinophilic Asthma

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04187976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing